Gujarat Inject
117.05
-5.30(-4.33%)
Market Cap₹171.44 Cr
PE Ratio98.67
IndustryHealthcare
Company Performance:
1D-4.33%
1M+14.64%
6M+244.06%
1Y+345.06%
5Y+4,716.87%
View Company Insightsright
More news about Gujarat Inject
27Mar 26
Gujarat Inject (Kerala) Limited Secures ₹3.11 Crore Solar Module Order from Earthwave Technology
Gujarat Inject (Kerala) Limited announced receiving a purchase order worth ₹3.11 crores from Earthwave Technology Private Limited for 3645 units of Solar PV Module GS12R-T132-GF-620WP. The order, disclosed under SEBI regulations, is scheduled for execution by March 2026 and involves no related party transactions.
 no imag found
27Mar 26
Gujarat Inject (Kerala) Limited Secures ₹1.21 Crore Solar Module Order from Perfect Renewtech
Gujarat Inject (Kerala) Limited has secured a purchase order worth ₹1.21 crores from Perfect Renewtech Private Limited for supplying 1355 solar PV modules. The order involves GS12R-T132-GF-620WP solar modules to be delivered by March 2026. The company confirmed this is a domestic contract with no related party transactions or promoter group interests involved.
 no imag found
16Mar 26
Gujarat Inject (Kerala) Limited Secures ₹0.61 Crore Solar Module Order from Surja Infra
Gujarat Inject (Kerala) Limited has secured a purchase order worth ₹0.61 crores from Surja Infra Private Limited for 678 solar PV modules of 590 WP capacity each. The domestic contract, scheduled for completion by March 2026, involves arranging modules at required sites and has been structured as an arm's length transaction with no related party involvement.
 no imag found
16Mar 26
Gujarat Inject (Kerala) Limited Secures ₹6.067 Crore Solar Module Order from Earthwave Technology
Gujarat Inject (Kerala) Limited has secured a ₹6.067 crore purchase order from Earthwave Technology Private Limited for 7,041 solar PV modules. The contract, valued exclusive of GST, involves Solar PV Module GS12R-T132-GF-620WP units to be delivered by March 2026. This domestic transaction represents a significant business development for the company, with no related party involvement.
 no imag found
14Feb 26
Gujarat Inject Kerala Limited Announces Q3FY26 Results Under Regulation 33
Gujarat Inject Kerala Limited reported Q3FY26 financial results showing revenue growth to ₹162.51 lakh from ₹13.80 lakh year-on-year, though net profit declined to ₹3.80 lakh from ₹6.75 lakh. The Board approved results on February 14, 2026 under SEBI regulations with statutory auditor review.
 no imag found
13Dec 25
Gujarat Inject (Kerala) Limited Independent Director Reena Mahatma Resigns Due to Personal Commitments
Gujarat Inject (Kerala) Limited announced the resignation of Independent Director Mrs. Reena Mahatma, effective December 9, 2025. She cited pre-occupation and personal commitments as reasons for departure. The company has complied with SEBI disclosure requirements by informing BSE about this board composition change.
 no imag found
09Dec 25
Gujarat Inject Kerala Limited Announces Changes in Board Composition
Gujarat Inject Kerala Limited has made changes to its board composition. Mr. Suresh Kumar Jain has been appointed as an Additional Director, serving as a Non-Executive Independent Director, effective February 14, 2024. Simultaneously, Mr. Kunal Karan's term as a Director ended on the same date.
 no imag found
25Jul 25
Gujarat Inject Kerala Limited Appoints Three New Directors, Including CFO
Gujarat Inject Kerala Limited (GIKL) has appointed three new directors during a board meeting on July 7, 2025. Rushiraj Zaverbhai Patel and Nileshbhai V. Rangholiya join as Additional Independent Directors for five-year terms. Dipak Diwan takes on dual roles as Additional Executive Director and Chief Financial Officer (CFO), with his CFO role starting July 15, 2025. All appointments are subject to shareholder approval and aim to enhance the company's governance and executive management.
 no imag found
Gujarat Inject
117.05
-5.30
(-4.33%)
1 Year Returns:+345.06%
Industry Peers
Sun Pharmaceutical
1,874.40
(+0.34%)
Divis Laboratories
6,753.50
(+0.10%)
Torrent Pharmaceuticals
4,504.40
(-0.21%)
Cipla
1,437.90
(+0.33%)
Dr Reddys Laboratories
1,328.40
(+2.08%)
Zydus Life Science
1,099.30
(-1.16%)
Lupin
2,367.60
(+0.42%)
Mankind Pharma
2,483.00
(-1.80%)
Aurobindo Pharma
1,530.60
(-0.23%)
Laurus Labs
1,454.20
(-1.81%)